NASDAQ: ORKA
Oruka Therapeutics Inc Stock

$13.87-0.16 (-1.14%)
Updated Jan 14, 2025
ORKA Price
$13.87
Fair Value Price
N/A
Market Cap
$485.43M
52 Week Low
$13.17
52 Week High
$53.88
P/E
-2.22x
P/B
1.42x
P/S
N/A
PEG
N/A
Dividend Yield
0%
Revenue
$0.00
Earnings
-$34.40M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$40M
Beta
0.51
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ORKA Overview

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ORKA's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

C
Value
C
Growth
C
Momentum
C
Sentiment
C
Safety
D
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ORKA
Ranked
#312 of 555

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ORKA news, forecast changes, insider trades & much more!

ORKA News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ORKA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ORKA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ORKA is good value based on its book value relative to its share price (1.42x), compared to the US Biotechnology industry average (4.73x)
P/B vs Industry Valuation
ORKA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ORKA due diligence checks available for Premium users.

Valuation

ORKA price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-2.22x
Industry
-107.1x
Market
30.21x

ORKA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.42x
Industry
4.73x
ORKA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ORKA's financial health

Profit margin

Revenue
$0.0
Net Income
-$28.6M
Profit Margin
0%
ORKA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$414.1M
Liabilities
$18.9M
Debt to equity
0.06
ORKA's short-term assets ($412.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ORKA's short-term assets ($412.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ORKA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ORKA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$34.9M
Investing
-$171.0k
Financing
$450.1M
ORKA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ORKA vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ORKAD$485.43M-1.11%-2.22x1.42x
ANNXD$482.87M-8.30%-4.36x1.46x
EYPTF$491.41M-7.10%-3.62x2.25x
DNAC$492.02M-3.39%-0.65x0.62x
XERSC$477.06M-2.44%-7.27x-16.84x

Oruka Therapeutics Stock FAQ

What is Oruka Therapeutics's quote symbol?

(NASDAQ: ORKA) Oruka Therapeutics trades on the NASDAQ under the ticker symbol ORKA. Oruka Therapeutics stock quotes can also be displayed as NASDAQ: ORKA.

If you're new to stock investing, here's how to buy Oruka Therapeutics stock.

What is the 52 week high and low for Oruka Therapeutics (NASDAQ: ORKA)?

(NASDAQ: ORKA) Oruka Therapeutics's 52-week high was $53.88, and its 52-week low was $13.17. It is currently -74.26% from its 52-week high and 5.32% from its 52-week low.

How much is Oruka Therapeutics stock worth today?

(NASDAQ: ORKA) Oruka Therapeutics currently has 34,998,550 outstanding shares. With Oruka Therapeutics stock trading at $13.87 per share, the total value of Oruka Therapeutics stock (market capitalization) is $485.43M.

Oruka Therapeutics stock was originally listed at a price of $5,241,807.05 in Dec 31, 1997. If you had invested in Oruka Therapeutics stock at $5,241,807.05, your return over the last 27 years would have been -100%, for an annualized return of -37.85% (not including any dividends or dividend reinvestments).

How much is Oruka Therapeutics's stock price per share?

(NASDAQ: ORKA) Oruka Therapeutics stock price per share is $13.87 today (as of Jan 14, 2025).

What is Oruka Therapeutics's Market Cap?

(NASDAQ: ORKA) Oruka Therapeutics's market cap is $485.43M, as of Jan 16, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Oruka Therapeutics's market cap is calculated by multiplying ORKA's current stock price of $13.87 by ORKA's total outstanding shares of 34,998,550.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.